AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

Journal of Lipid Research

Volumn 54, Issue 1, 2013, Pages 134-151

  Pinkosky, Stephen L ^a   Filippov, Sergey ^a   Srivastava, Rai Ajit K ^a   Hanselman, Jeffrey C ^a   Bradshaw, Cheryl D ^a   Hurley, Timothy R ^a   Cramer, Clay T ^a   Spahr, Mark A ^a   Brant, Ashley F ^a   Houghton, Jacob L ^b   Baker, Chris ^c   Naples, Mark ^c   Adeli, Khosrow ^c   Newton, Roger S ^a  

^a Esperion Therapeutics Inc   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiovascular disease; Cholesterol synthesis; Fatty acid oxidation; Fatty acid synthesis; LDL cholesterol; Metabolic syndrome

Indexed keywords

3 HYDROXYBUTYRIC ACID; 8 HYDROXY 2,2,14,14 TETRAMETHYLPENTADECANEDIOIC ACID; ADENOSINE TRIPHOSPHATE CITRATE LYASE; ANTILIPEMIC AGENT; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIVER KINASE BETA1; LOW DENSITY LIPOPROTEIN; PROTEIN KINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FATTY ACID SYNTHESIS; GLUCONEOGENESIS; GLYCEMIC CONTROL; HYPERLIPIDEMIA; IN VITRO STUDY; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER CELL; MALE; MORNING DOSAGE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; STEROL SYNTHESIS; SYRIAN HAMSTER; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ATP CITRATE (PRO-S)-LYASE; BIOLOGICAL MARKERS; CALCIUM; CARBOHYDRATE METABOLISM; CRICETINAE; DICARBOXYLIC ACIDS; DIET; DYSLIPIDEMIAS; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITORS; FATTY ACIDS; FEMALE; GLUCAGON; GLUCOSE; HEP G2 CELLS; HUMANS; LIPID METABOLISM; LIVER; MALE; MICE; MOLECULAR TARGETED THERAPY; OBESITY; PROTEIN-SERINE-THREONINE KINASES; RATS; SIGNAL TRANSDUCTION; STEROLS;

EID: 84871226706     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M030528     Document Type: Article

References (106)

1. Rosamond, W., K. Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. Haase, M. Ho, V. Howard, B. Kissela, et al. 2007. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 115: e69-e171. (Pubitemid 46226160)
2. Cannon, C. P., E. Braunwald, C. H. McCabe, D. J. Rader, J. L. Rouleau, R. Belder, S. V. Joyal, K. A. Hill, M. A. Pfeffer, and A. M. Skene. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350: 1495-1504. (Pubitemid 38477774)
3. Fonarow, G. C., and K. E. Watson. 2003. Effective strategies for long-term statin use. Am. J. Cardiol. 92: 27i-34i. (Pubitemid 36831112)
4. Kastelein, J. J. 2003. The future of lipid-lowering therapy: the big picture. Neth. J. Med. 61: 35-39.
5. Vladutiu, G. D. 2008. Genetic predisposition to statin myopathy. Curr. Opin. Rheumatol. 20: 648-655.
6. Vandenberg, B. F., and J. Robinson. 2010. Management of the patient with statin intolerance. Curr. Atheroscler. Rep. 12: 48-57.
7. Mancini, G. B., S. Baker, J. Bergeron, D. Fitchett, J. Frohlich, J. Genest, M. Gupta, R. A. Hegele, D. Ng, and J. Pope. 2011. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can. J. Cardiol. 27: 635-662.
8. Harris, L. J., R. Thapa, M. Brown, S. Pabbathi, R. D. Childress, M. Heimberg, R. Braden, and M. B. Elam. 2011. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J. Clin. Lipidol. 5: 299-307.
9. Cohen, J. D., E. A. Brinton, M. K. Ito, and T. A. Jacobson. 2012. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 6: 208-215.
10. Thompson, P. D., P. Clarkson, and R. H. Karas. 2003. Statin-associated myopathy. JAMA. 289: 1681-1690. (Pubitemid 37430274)
11. Culver, A. L., I. S. Ockene, R. Balasubramanian, B. C. Olendzki, D. M. Sepavich, J. Wactawski-Wende, J. E. Manson, Y. Qiao, S. Liu, P. A. Merriam, et al. 2012. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172: 144-152.
12. Cramer, C. T., B. Goetz, K. L. Hopson, G. J. Fici, R. M. Ackermann, S. C. Brown, C. L. Bisgaier, W. G. Rajeswaran, D. C. Oniciu, and M. E. Pape. 2004. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J. Lipid Res. 45: 1289-1301. (Pubitemid 38802632)
13. Hanselman, J. C., C. D. Bradshaw, A. F. Brant, C. T. Cramer, T. R. Hurley, S. L. Pinkosky, M. A. Spahr, J. G. Washburn, R. S. Newton, and R. A. K. Srivastava. 2011. ETC-1002 reduces circulating and hepatic triglyceride content and improves glycemic control in KKAy mice. (Abstract 554 in ATVB 2011 Scientific Sessions, Chicago, IL, April 28-30, 2011).
14. Cramer, C. T., R. A. Srivastava, J. Lutostanski, C. L. Bisgaier, and R. S. Newton. 2011. ETC-1002: a novel small molecule inhibitor of lipogenesis improves plasma lipid profile and inhibits atherosclerosis progression in LDLr -/- Mouse by a lipid-dependent and independent mechanism. (Abstract 404 in ATVB 2011 Scientific Sessions, Chicago, IL, April 28-30, 2011).
15. Ballantyne, C. M., M. Davidson, D. MacDougall, J. Margulies, and L. DiCarlo. 2012. ETC-1002 lowers LDL-C and beneficially modulates other cardio-metabolic risk factors in hypercholesterolemic subjects with either normal or elevated triglycerides. J. Am. Coll. Cardiol. 59: E1625.
16. Ulrich, R. G., D. G. Aspar, C. T. Cramer, R. F. Kletzien, and L. C. Ginsberg. 1990. Isolation and culture of hepatocytes from the cynomolgus monkey (Macaca fascicularis). In Vitro Cell. Dev. Biol. 26: 815-823. (Pubitemid 20307013)
17. Slayback, J. R., L. W. Cheung, and R. P. Geyer. 1977. Quantitative extraction of microgram amounts of lipid from cultured human cells. Anal. Biochem. 83: 372-384. (Pubitemid 8269789)
18. Ma, Z., C. H. Chu, and D. Cheng. 2009. A novel direct homogeneous assay for ATP citrate lyase. J. Lipid Res. 50: 2131-2135.
19. Wang, Q., S. Li, L. Jiang, Y. Zhou, Z. Li, M. Shao, W. Li, and Y. Liu. 2010. Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice. J. Lipid Res. 51: 2516-2526.
20. Wang, Q., L. Jiang, J. Wang, S. Li, Y. Yu, J. You, R. Zeng, X. Gao, L. Rui, W. Li, et al. 2009. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology. 49: 1166-1175.
21. Rodríguez-Enríquez, S., O. Juárez, J. S. Rodríguez-Zavala, and R. Moreno-Sanchez. 2001. Multisite control of the Crabtree effect in ascites hepatoma cells. Eur. J. Biochem. 268: 2512-2519.
22. Marroquin, L. D., J. Hynes, J. A. Dykens, J. D. Jamieson, and Y. Will. 2007. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97: 539-547. (Pubitemid 47073868)
23. Buhl, E. S., N. Jessen, R. Pold, T. Ledet, A. Flyvbjerg, S. B. Pedersen, O. Pedersen, O. Schmitz, and S. Lund. 2002. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 51: 2199-2206. (Pubitemid 34729025)
24. Dietschy, J. M., S. D. Turley, and D. K. Spady. 1993. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34: 1637-1659. (Pubitemid 23298709)
25. Quig, D. W., C. M. Arbeeny, and D. B. Zilversmit. 1991. Effects of hyperlipidemias in hamsters on lipid transfer protein activity and unidirectional cholesteryl ester transfer in plasma. Biochim. Biophys. Acta. 1083: 257-264.
26. Taghibiglou, C., D. Rudy, S. C. Van Iderstine, A. Aiton, D. Cavallo, R. Cheung, and K. Adeli. 2000. Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes. J. Lipid Res. 41: 499-513. (Pubitemid 30220653)
27. Spady, D. K., and J. M. Dietschy. 1988. Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster. J. Clin. Invest. 81: 300-309. (Pubitemid 18075220)
28. Srivastava, R. A. 2011. Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis- susceptible F(1)B hamsters. Atherosclerosis. 214: 86-93.
29. Srivastava, R. A., and S. He. 2010. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. Mol. Cell. Biochem. 345: 197-206.
30. Guo, Q., P. R. Wang, D. P. Milot, M. C. Ippolito, M. Hernandez, C. A. Burton, S. D. Wright, and Y. Chao. 2001. Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim. Biophys. Acta. 1533: 220-232. (Pubitemid 33127273)
31. Ohtani, H., K. Hayashi, Y. Hirata, S. Dojo, K. Nakashima, E. Nishio, H. Kurushima, M. Saeki, and G. Kajiyama. 1990. Effects of dietary cholesterol and fatty acids on plasma cholesterol level and hepatic lipoprotein metabolism. J. Lipid Res. 31: 1413-1422. (Pubitemid 20261905)
32. Wang, P. R., Q. Guo, M. Ippolito, M. Wu, D. Milot, J. Ventre, T. Doebber, S. D. Wright, and Y. S. Chao. 2001. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur. J. Pharmacol. 427: 285-293. (Pubitemid 32913296)
33. He, M., H. Su, W. Gao, S. M. Johansson, Q. Liu, X. Wu, J. Liao, A. A. Young, T. Bartfai, and M. W. Wang. 2010. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. PLoS ONE. 5: e14205.
34. Jang, E. H., J. S. Moon, J. H. Ko, C. W. Ahn, H. H. Lee, J. K. Shin, C. S. Park, and J. H. Kang. 2008. Novel black soy peptides with antiobesity effects: activation of leptin-like signaling and AMP-activated protein kinase. Int. J. Obes. (Lond.) 32: 1161-1170.
35. Konstantopoulos, N., J. C. Molero, S. L. McGee, B. Spolding, T. Connor, M. de Vries, S. Wanyonyi, R. Fahey, S. Morrison, C. Swinton, et al. 2012. Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo. Diabetes. 61: 2146-2154.
36. Lee, Y. S., P. Li, J. Y. Huh, I. J. Hwang, M. Lu, J. I. Kim, M. Ham, S. Talukdar, A. Chen, W. J. Lu, et al. 2011. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes. 60: 2474-2483.
37. Li, P., M. Lu, M. T. Nguyen, E. J. Bae, J. Chapman, D. Feng, M. Hawkins, J. E. Pessin, D. D. Sears, A. K. Nguyen, et al. 2010. Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet- induced obese mice. J. Biol. Chem. 285: 15333-15345.
38. Park, J. S., S. D. Rhee, W. H. Jung, N. S. Kang, H. Y. Kim, S. K. Kang, J. H. Ahn, and K. Y. Kim. 2012. Anti-diabetic and anti-adipogenic effects of a novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice. Eur. J. Pharmacol. 691: 19-27.
39. Watson, J. A., M. Fang, and J. M. Lowenstein. 1969. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch. Biochem. Biophys. 135: 209-217.
40. Lowenstein, J. M. 1971. Effect of (-)-hydroxycitrate on fatty acid synthesis by rat liver in vivo. J. Biol. Chem. 246: 629-632.
41. Cheema-Dhadli, S., M. L. Halperin, and C. C. Leznoff. 1973. Inhibition of enzymes which interact with citrate by (-)hydroxycitrate and 1,2,3,-tricarboxybenzene. Eur. J. Biochem. 38: 98-102.
42. Elshourbagy, N. A., J. C. Near, P. J. Kmetz, G. M. Sathe, C. Southan, J. E. Strickler, M. Gross, J. F. Young, T. N. Wells, and P. H. Groot. 1990. Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. J. Biol. Chem. 265: 1430-1435.
43. Barth, C., J. Hackenschmidt, H. Ullmann, and K. Decker. 1972. Inhibition of cholesterol synthesis by (-)-hydroxycitrate in perfused rat liver. Evidence for an extramitochondrial mevalonate synthesis from acetyl coenzyme A. FEBS Lett. 22: 343-346.
44. Brunengraber, H., J. R. Sabine, M. Boutry, and J. M. Lowenstein. 1972. 3-Hydroxysterol synthesis by the liver. Arch. Biochem. Biophys. 150: 392-396.
45. Hamilton, J. G., A. C. Sullivan, and D. Kritchevsky. 1977. Hupolipidemic activity of (-)-hydroxycitrate. Lipids. 12: 1-9.
46. Sullivan, A. C., J. G. Hamilton, O. N. Miller, and V. R. Wheatley. 1972. Inhibition of lipogenesis in rat liver by (-)-hydroxycitrate. Arch. Biochem. Biophys. 150: 183-190.
47. Berkhout, T. A., L. M. Havekes, N. J. Pearce, and P. H. Groot. 1990. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem. J. 272: 181-186.
48. Pearce, N. J., J. W. Yates, T. A. Berkhout, B. Jackson, D. Tew, H. Boyd, P. Camilleri, P. Sweeney, A. D. Gribble, A. Shaw, et al. 1998. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J. 334: 113-119.
49. Wellen, K. E., G. Hatzivassiliou, U. M. Sachdeva, T. V. Bui, J. R. Cross, and C. B. Thompson. 2009. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 324: 1076-1080.
50. Jeninga, E. H., K. Schoonjans, and J. Auwerx. 2010. Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility. Oncogene. 29: 4617-4624.
51. Guarente, L. 2011. The logic linking protein acetylation and metabolism. Cell Metab. 14: 151-153.
52. Carling, D., V. A. Zammit, and D. G. Hardie. 1987. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 223: 217-222.
53. Clark, H., D. Carling, and D. Saggerson. 2004. Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. Eur. J. Biochem. 271: 2215-2224. (Pubitemid 38747990)
54. de Lange, P., P. Farina, M. Moreno, M. Ragni, A. Lombardi, E. Silvestri, L. Burrone, A. Lanni, and F. Goglia. 2006. Sequential changes in the signal transduction responses of skeletal muscle following food deprivation. FASEB J. 20: 2579-2581.
55. Suchankova, G., M. Tekle, A. K. Saha, N. B. Ruderman, S. D. Clarke, and T. W. Gettys. 2005. Dietary polyunsaturated fatty acids enhance hepatic AMP-activated protein kinase activity in rats. Biochem. Biophys. Res. Commun. 326: 851-858. (Pubitemid 39655997)
56. Fediuc, S., M. P. Gaidhu, and R. B. Ceddia. 2006. Regulation of AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation by palmitate in skeletal muscle cells. J. Lipid Res. 47: 412-420. (Pubitemid 43276927)
57. Watt, M. J., G. R. Steinberg, Z. P. Chen, B. E. Kemp, and M. A. Febbraio. 2006. Fatty acids stimulate AMP-activated protein kinase and enhance fatty acid oxidation in L6 myotubes. J. Physiol. 574: 139-147. (Pubitemid 43905803)
58. Wang, X., L. Zhou, G. Li, T. Luo, Y. Gu, L. Qian, X. Fu, F. Li, J. Li, and M. Luo. 2007. Palmitate activates AMP-activated protein kinase and regulates insulin secretion from beta cells. Biochem. Biophys. Res. Commun. 352: 463-468. (Pubitemid 44838509)
59. Sakakibara, S., T. Yamauchi, Y. Oshima, Y. Tsukamoto, and T. Kadowaki. 2006. Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice. Biochem. Biophys. Res. Commun. 344: 597-604.
60. Pelletier, A., and L. Coderre. 2007. Ketone bodies alter dinitrophenol-induced glucose uptake through AMPK inhibition and oxidative stress generation in adult cardiomyocytes. Am. J. Physiol. Endocrinol. Metab. 292: E1325-E1332. (Pubitemid 46684601)
61. Wu, Y., P. Song, J. Xu, M. Zhang, and M. H. Zou. 2007. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J. Biol. Chem. 282: 9777-9788. (Pubitemid 47104626)
62. Klumpp, S., M. C. Thissen, and J. Krieglstein. 2006. Protein phosphatases types 2Calpha and 2Cbeta in apoptosis. Biochem. Soc. Trans. 34: 1370-1375. (Pubitemid 46769057)
63. Za'tara, G., J. Bar-Tana, B. Kalderon, M. Suter, E. Morad, D. Samovski, D. Neumann, and R. Hertz. 2008. AMPK activation by long chain fatty acyl analogs. Biochem. Pharmacol. 76: 1263-1275.
64. Liu, Q., M. S. Gauthier, L. Sun, N. Ruderman, and H. Lodish. 2010. Activation of AMP-activated protein kinase signaling pathway by adiponectin and insulin in mouse adipocytes: requirement of acyl-CoA synthetases FATP1 and Acsl1 and association with an elevation in AMP/ATP ratio. FASEB J. 24: 4229-4239.
65. Schenk, S., M. Saberi, and J. M. Olefsky. 2008. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118: 2992-3002.
66. Galic, S., M. D. Fullerton, J. D. Schertzer, S. Sikkema, K. Marcinko, C. R. Walkley, D. Izon, J. Honeyman, Z. P. Chen, B. J. van Denderen, et al. 2011. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 121: 4903-4915.
67. Adler, A. I., E. J. Shaw, T. Stokes, and F. Ruiz. 2009. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ. 338: b1668.
68. Nathan, D. M., J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, and B. Zinman. 2009. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32: 193-203.
69. Turner, R. C., C. A. Cull, V. Frighi, and R. R. Holman. 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 281: 2005-2012. (Pubitemid 29254858)
70. El-Mir, M. Y., V. Nogueira, E. Fontaine, N. Averet, M. Rigoulet, and X. Leverve. 2000. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275: 223-228. (Pubitemid 30038975)
71. Owen, M. R., E. Doran, and A. P. Halestrap. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348: 607-614. (Pubitemid 30410251)
72. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108: 1167-1174. (Pubitemid 32995375)
73. Koo, S. H., L. Flechner, L. Qi, X. Zhang, R. A. Screaton, S. Jeffries, S. Hedrick, W. Xu, F. Boussouar, P. Brindle, et al. 2005. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 437: 1109-1111.
74. Barthel, A., D. Schmoll, K. D. Kruger, R. A. Roth, and H. G. Joost. 2002. Regulation of the forkhead transcription factor FKHR (FOXO1a) by glucose starvation and AICAR, an activator of AMP-activated protein kinase. Endocrinology. 143: 3183-3186. (Pubitemid 34809893)
75. Matsumoto, M., A. Pocai, L. Rossetti, R. A. Depinho, and D. Accili. 2007. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6: 208-216. (Pubitemid 47336849)
76. Yoon, J. C., P. Puigserver, G. Chen, J. Donovan, Z. Wu, J. Rhee, G. Adelmant, J. Stafford, C. R. Kahn, D. K. Granner, et al. 2001. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 413: 131-138. (Pubitemid 32867868)
77. Leclerc, I., C. Lenzner, L. Gourdon, S. Vaulont, A. Kahn, and B. Viollet. 2001. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes. 50: 1515-1521. (Pubitemid 33639590)
78. Kawaguchi, T., K. Osatomi, H. Yamashita, T. Kabashima, and K. Uyeda. 2002. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J. Biol. Chem. 277: 3829-3835. (Pubitemid 34968632)
79. Munday, M. R., D. G. Campbell, D. Carling, and D. G. Hardie. 1988. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175: 331-338.
80. Carlson, C. A., and K. H. Kim. 1974. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. Arch. Biochem. Biophys. 164: 478-489.
81. Beg, Z. H., J. A. Stonik, and H. B. Brewer, Jr. 1987. Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. Metabolism. 36: 900-917. (Pubitemid 17135086)
82. Meyer, K., A. Volkl, R. Endele, H. F. Kuhnle, and J. Pill. 1999. Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPARalpha). Arch. Toxicol. 73: 440-450. (Pubitemid 30010245)
83. Pill, J., and H. F. Kuhnle. 1999. BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Metabolism. 48: 34-40. (Pubitemid 29035558)
84. Bremer, J. 2001. The biochemistry of hypo- and hyperlipidemic fatty acid derivatives: metabolism and metabolic effects. Prog. Lipid Res. 40: 231-268. (Pubitemid 32544958)
85. Morken, T., P. Bohov, J. Skorve, R. Ulvik, P. Aukrust, R. K. Berge, and J. K. Livden. 2011. Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis-a pilot study. Scand. J. Clin. Lab. Invest. 71: 269-273.
86. Skrede, S., H. N. Sorensen, L. N. Larsen, H. H. Steineger, K. Hovik, O. S. Spydevold, R. Horn, and J. Bremer. 1997. Thia fatty acids, metabolism and metabolic effects. Biochim. Biophys. Acta. 1344: 115-131. (Pubitemid 27046437)
87. Berge, R. K., J. Skorve, K. J. Tronstad, K. Berge, O. A. Gudbrandsen, and H. Grav. 2002. Metabolic effects of thia fatty acids. Curr. Opin. Lipidol. 13: 295-304. (Pubitemid 34592287)
88. Russell, J. C., R. M. Amy, S. E. Graham, P. J. Dolphin, G. O. Wood, and J. Bar-Tana. 1995. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by beta, beta'-tetramethylhexadecanedioic acid (MEDICA 16). Arterioscler. Thromb. Vasc. Biol. 15: 918-923.
89. Tzur, R., G. Rose-Kahn, J. H. Adler, and J. Bar-Tana. 1988. Hypolipidemic, antiobesity, and hypoglycemic-hypoinsulinemic effects of beta,beta'-methyl-substituted hexadecanedioic acid in sand rats. Diabetes. 37: 1618-1624. (Pubitemid 19004943)
90. Bar-Tana, J., S. Ben-Shoshan, J. Blum, Y. Migron, R. Hertz, J. Pill, G. Rose-Khan, and E. C. Witte. 1989. Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids. J. Med. Chem. 32: 2072-2084. (Pubitemid 19224168)
91. McCune, S. A., and R. A. Harris. 1979. Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. J. Biol. Chem. 254: 10095-10101. (Pubitemid 10162030)
92. Parker, R. A., T. Kariya, J. M. Grisar, and V. Petrow. 1977. 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. J. Med. Chem. 20: 781-791. (Pubitemid 8096806)
93. Bisgaier, C. L., A. D. Essenburg, B. C. Barnett, B. J. Auerbach, S. Haubenwallner, T. Leff, A. D. White, P. Creger, M. E. Pape, T. J. Rea, et al. 1998. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J. Lipid Res. 39: 17-30. (Pubitemid 28063539)
94. Rose-Kahn, G., and J. Bar-Tana. 1985. Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omegadicarboxylic acids in cultured rat hepatocytes. J. Biol. Chem. 260: 8411-8415. (Pubitemid 15011810)
95. Bar-Tana, J., G. Rose-Kahn, and M. Srebnik. 1985. Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in the rat in vivo. J. Biol. Chem. 260: 8404-8410. (Pubitemid 15249849)
96. Hertz, R., V. Sheena, B. Kalderon, I. Berman, and J. Bar-Tana. 2001. Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators. Biochem. Pharmacol. 61: 1057-1062. (Pubitemid 32285472)
97. Hertz, R., J. Bishara-Shieban, and J. Bar-Tana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J. Biol. Chem. 270: 13470-13475.
98. Kalderon, B., R. Hertz, and J. Bar-Tana. 1992. Tissue selective modulation of redox and phosphate potentials by beta,beta'-methyl-substituted hexadecanedioic acid. Endocrinology. 131: 1629-1635.
99. Rose-Kahn, G., and J. Bar-Tana. 1990. Inhibition of rat liver acetyl-CoA carboxylase by beta, beta'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16). Biochim. Biophys. Acta. 1042: 259-264. (Pubitemid 20043458)
100. Raspé, E., L. Madsen, A. M. Lefebvre, I. Leitersdorf, L. Gelman, J. Peinado-Onsurbe, J. Dallongeville, J. C. Fruchart, R. Berge, and B. Staels. 1999. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. J. Lipid Res. 40: 2099-2110.
101. Vega, R. B., J. M. Huss, and D. P. Kelly. 2000. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20: 1868-1876. (Pubitemid 30100203)
102. Baur, J. A., K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, V. V. Prabhu, J. S. Allard, G. Lopez-Lluch, K. Lewis, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444: 337-342. (Pubitemid 44764104)
103. Puigserver, P., J. Rhee, J. Donovan, C. J. Walkey, J. C. Yoon, F. Oriente, Y. Kitamura, J. Altomonte, H. Dong, D. Accili, et al. 2003. Insulin-regulated hepatic gluconeogenesis through FOXO1- PGC-1alpha interaction. Nature. 423: 550-555. (Pubitemid 36648580)
104. Hong, Y. H., U. S. Varanasi, W. Yang, and T. Leff. 2003. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J. Biol. Chem. 278: 27495-27501. (Pubitemid 36899932)
105. Brown, M. S., and J. L. Goldstein. 2008. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7: 95-96. (Pubitemid 351168559)
106. Zatara, G., R. Hertz, M. Shaked, N. Mayorek, E. Morad, E. Grad, A. Cahan, H. D. Danenberg, T. G. Unterman, and J. Bar-Tana. 2011. Suppression of FoxO1 activity by long-chain fatty acyl analogs. Diabetes. 60: 1872-1881.